TD Asset Management Inc Has $88.16 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

TD Asset Management Inc lessened its position in Becton, Dickinson and Company (NYSE:BDX) by 13.5% in the first quarter, HoldingsChannel reports. The fund owned 384,883 shares of the medical instruments supplier’s stock after selling 60,304 shares during the quarter. TD Asset Management Inc’s holdings in Becton, Dickinson and Company were worth $88,161,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in Becton, Dickinson and Company by 50.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier’s stock valued at $18,808,000 after acquiring an additional 27,581 shares during the period. Foster Victor Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company in the first quarter valued at approximately $6,406,000. GAMMA Investing LLC grew its stake in Becton, Dickinson and Company by 29.9% in the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock valued at $744,000 after acquiring an additional 748 shares during the period. Finally, Ritholtz Wealth Management purchased a new position in shares of Becton, Dickinson and Company during the first quarter valued at approximately $224,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Shan sold 1,166 shares of the business’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the transaction, the executive vice president owned 4,575 shares of the company’s stock, valued at approximately $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $185.52 on Friday. The business’s fifty day simple moving average is $174.31 and its 200 day simple moving average is $202.53. The firm has a market capitalization of $53.17 billion, a P/E ratio of 35.40, a price-to-earnings-growth ratio of 1.40 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.07. The firm had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The business’s revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.17 earnings per share. As a group, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.24%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 79.39%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BDX. Barclays cut their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 3rd. Bank of America cut Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 target price on the stock. in a research report on Thursday, May 1st. William Blair cut Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 1st. Morgan Stanley cut their target price on Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 6th. Finally, Citigroup cut Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and cut their target price for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $219.22.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.